Frequent occurrence of cerebral demyelination in adrenomyeloneuropathy

Marlijn de BeerB M van Geel


To study the frequency of additional cerebral demyelination in Dutch patients with adrenomyeloneuropathy (AMN). Consecutive patients with AMN from the Dutch X-linked adrenoleukodystrophy cohort without cerebral demyelination on MRI at inclusion, seen between January 1, 1992, and January 1, 1999, were included. Primary endpoints were brain involvement, death, or the end of follow-up on January 1, 2011. Three levels of certainty were used for cerebral demyelination: (1) signs and symptoms reported by relatives and treating physicians, confirmed by brain MRI; if follow-up MRIs were not available, (2) based upon information from treating physicians and relatives, and (3) based upon information obtained from relatives only. Results were compared with a study published in 2001, in which 13/68 (19.1%) patients with AMN developed cerebral demyelination in 9.5 ± 5.5 years. Differences of the proportions of patients with cerebral demyelination and their 95% confidence intervals (CIs) were calculated. Of 27 patients with AMN, 17 (63%) developed cerebral demyelination 10.2 ± 6.9 years after onset of myelo(neuro)pathy. Mean survival was 3.4 ± 2.9 years. Brain involvement was higher in Dutch patients with AMN (difference 44%, 95% CI 0.23-0.6...Continue Reading


Feb 11, 2016·Clinical Case Reports·Morten A HornChantal M E Tallaksen
Apr 14, 2016·Molecular Genetics and Metabolism·Martin J A SchackmannStephan Kemp
Jul 18, 2016·Journal of the Neurological Sciences·Veronika DunklHelmar C Lehmann
Jun 18, 2016·Nature Reviews. Endocrinology·Stephan KempMarc Engelen
Jul 20, 2016·Biochimica Et Biophysica Acta·Catherine E van EngenMathieu Barbier
Apr 29, 2016·PloS One·Malu-Clair van de BeekStephan Kemp
Feb 3, 2018·Journal of Inherited Metabolic Disease·Sandra SirrsEric M Yoshida
Dec 12, 2018·Brain : a Journal of Neurology·Irene C HuffnagelMarc Engelen
Nov 27, 2019·Current Treatment Options in Neurology·Eric J MallackFlorian S Eichler
Oct 13, 2018·Orphanet Journal of Rare Diseases·Alice BesseyAnthea Sutton
Feb 5, 2019·Frontiers in Neurology·Felipe Franco da GraçaMarcondes C França
May 5, 2020·Endocrine Reviews·Jia ZhuJoseph A Majzoub
Oct 1, 2020·Journal of Neurology·Aaron M CarlsonKeith Van Haren
Feb 1, 2015·Brain : a Journal of Neurology·James D Weisfeld-AdamsFred D Lublin
Sep 27, 2019·Brain and Behavior·Chao WangJingyao Liu
Jul 17, 2020·Frontiers in Cell and Developmental Biology·Phillip A RichmondClara D M van Karnebeek
Sep 22, 2020·Curēus·Aniruddh MannariGhassan Bachuwa
Feb 23, 2020·Journal of Inherited Metabolic Disease·Stephanie I W van de StadtMarc Engelen
Jul 7, 2020·Frontiers in Cell and Developmental Biology·Rinse W BarendsenStephan Kemp
Jun 22, 2021·Postgraduate Medicine·Chueh Lin HsuWojciech Kozubski
Jul 1, 2021·Neuropediatrics·Stephanie I W van de StadtMarc Engelen
Nov 27, 2021·Molecular Genetics & Genomic Medicine·Siwen LiuYinan Ma

❮ Previous
Next ❯

Related Concepts

Related Feeds


Adrenoleukodystrophy (ALD), the most frequent peroxisomal disorder, is an X-linked disorder caused by a defect in the metabolism of long chain fatty acids leading to demyelination, neurodegeneration, and death. Here is the latest research.